A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
出版年份 2013 全文链接
标题
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 24, Issue 7, Pages 1777-1785
出版商
Oxford University Press (OUP)
发表日期
2013-03-20
DOI
10.1093/annonc/mdt057
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies.
- (2017) Y. Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
- (2017) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors
- (2012) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status
- (2011) M. Ii et al. CLINICAL CANCER RESEARCH
- Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
- (2011) Uzma Asghar et al. Clinical Colorectal Cancer
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models
- (2011) P. J. Beltran et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types
- (2010) Paula J. Kaplan-Lefko et al. CANCER BIOLOGY & THERAPY
- The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
- (2010) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer
- (2010) D. P. McLornan et al. CLINICAL CANCER RESEARCH
- Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer
- (2010) Diane Lauren Reidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study
- (2009) Stephen Leong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
- (2009) P. J. Beltran et al. MOLECULAR CANCER THERAPEUTICS
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer
- (2008) Daisuke Takahari et al. ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More